The Effects of Non-invasive Brain Stimulation on Treatment Adherence in Schizophrenia

What this study is about

This study seeks to explore the effects of transcranial direct current stimulation (tDCS), a non-invasive method of brain stimulation, as an adjunctive treatment to improve antipsychotic medication adherence in patients with schizophrenia (SCZ). The investigators hypothesize that 20 sessions of tDCS will improve medication nonadherence in patients with SCZ.

Who can join (things the study team will check)

✅ You may be able to join if…

• Male or female participants of any race or ethnicity
• Inpatients or outpatients ≥18 years of age
• DSM-V diagnosis of SCZ or schizoaffective disorder
• Capable of consenting to participate in the research study
• On a stable dose of antipsychotic drug and other concomitant medications for at least 2 months, and unlikely to undergo changes in dose during the study

🚫 You may not be able to join if…

• Unwilling or incapable to consent to the study based on the MacArthur Test of Competence
• Unstable medical or any concomitant major medical or neurological illness, including a history of seizures
• Acute suicidal or homicidal ideation
• Formal thought disorder rating ≥3 on the Positive and Negative Syndrome Scale (PANSS) P2 conceptual disorganization item
• DSM-V substance dependence (except caffeine and nicotine) within 1 month of entering the study*
• Positive urine drug screen except for cannabis/marijuana at the screening visit
• Metal implants or pacemaker precluding an MRI scan or other contraindications to MRI (eg., claustrophobia)
• Pregnancy
• Score < 32 on the Wide Range Achievement Test-III
  • Substance misuse: In addition to impaired insight, substance misuse is one of the principle contributors to medication nonadherence. To minimize the possibility of its influence, participants with a DSM-V diagnosis of substance dependence within 1 month of entering the study or a positive urine drug test (except for cannabis/marijuana) at the screening visit will be excluded. Substance use and urine drug screens will be assessed at subsequent study visits.

Where this trial is running

• Centre for Addiction and Mental Health, Toronto, Ontario, Canada

Who to contact

Philip Gerretsen, MD, PhD · 416-535-8501 · philip.gerretsen@camh.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT04033679.